



Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.^{1,2}

1. AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.

2. AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

Management Team

Dr. Terrence W. Norchi

President, Chief Executive Officer and Director

Michael S. Abrams

Chief Financial Officer

Recent News

Tuesday, April 25, 2023 - 06:50 AM

[Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care \("SAWC"\)](#)

Wednesday, April 05, 2023 - 06:50 AM

[Dedicated HCPCS Billing Code for Arch Therapeutics' AC5® Advanced Wound System Now In Effect](#)

Thursday, March 09, 2023 - 07:50 AM

[Arch Therapeutics' AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services](#)

Tuesday, March 07, 2023 - 07:50 AM


[Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities](#)

Contact Information

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702

OTCQB: ARTH



Share Price	\$2.05
Volume	105
Shares Outstanding	1,262,513
Market Cap	\$2.59m
52 Week High	\$12.00
52 Week Low	\$1.73

as of 07/25/2023

Wednesday, January 18, 2023 - 07:35 AM

[Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System](#)

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.